Senate FDA Appropriation Includes $2M For CBD Enforcement Discretion Policy

Instruction in Appropriations Committee report on FY 2020 spending bill garners support from some stakeholders while others say setting a safe level of CBD's use in non-drug products should come first. Senate appropriators endorses FDA policy that regulations allowing sales of CBD non-drug products "not discourage the development of new drugs."

WASHINGTON - JULY 18: A sign at the entrance to a Senate Appropriations Committee hearing room in Washington, DC on July 18, 2017. The US Senate is the upper chamber of the United States Congress. - Image

US Senate appropriators direct the Food and Drug Administration to establish an enforcement discretion policy for products containing hemp-derived cannabidiol, but omit a step their House counterparts request of first setting a safe level for the ingredient's use in food and dietary supplements.

The instruction stated in the Senate Appropriations Committee's report on is fiscal year 2020 spending bill for agriculture, rural...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Regulation

More from Policy & Regulation